Senz Oncology is a biotechnology company with an oncology focus. We are developing medicines to provide new treatment options to cancer patients.

Our lead product VAL-1000 is being developed to treat patients with leukaemias and other blood cancers.

Senz Oncology will be attending the following conferences:

  • JP Morgan 2016, 11-14 January, San Francisco, CA, USA